Investors

Virpax Pharmaceuticals is collaborating with the best drug development minds in the pharmaceutical industry. Our innovative drug delivery platforms have been formulated, so we may optimize how our non-addictive post operative pain, severe pain, and CNS disorder medications are delivered to maximize efficacy.

As part of our ongoing non-dilutive funding strategy, Virpax will work with our banking advisors to pursue sub-licensing, joint ventures, and co-development opportunities with reputable global strategic partners. Virpax will seek University partnerships and grant opportunities. As well, we will continue seeking additional government and military grants and CRADA awards for all of our Rx product candidates.

• US Army Institute of Surgical Research (USAISR)
  Awarded 5/05/2022
  Extended 10/09/2023
  
• National Center for Advancing Translational Sciences (NCATS)
  Awarded 8/31/2020
• National Institute of Neurological Disorders and Stroke (NINDS)
  Awarded 4/19/2023